A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, randomized, placebo-controlled, double-blind, multicenter clinical trial
of pertuzumab in combination with gemcitabine relative to placebo in combination with
gemcitabine in subjects with advanced ovarian, primary peritoneal, or fallopian tube cancer
that is resistant to platinum-based chemotherapy.